Whitening composition containing deoxyvasicinone as an active ingredient and a method for producing said deoxyvasicinone

Whitening composition for improving hyperpigmentation disorders containing deoxyvasicinone as an active ingredient

This technology is a whitening composition containing 1 ppm to 100 ppm of the alkaloid deoxyvasicinone—or its salts, hydrates, or solvates—isolated and purified from natural sources as an active ingredient. It can be widely formulated into cosmetic, pharmaceutical, and food products.

Melanin, produced in melanocytes by enzymes such as tyrosinase, can accumulate excessively due to UV exposure, hormones, and stress, leading to pigmentation issues like melasma, freckles, and age spots. Existing whitening agents have often been limited by insufficient efficacy duration and skin safety concerns.

This technology confirms through melanin production assays that deoxyvasicinone inhibits melanin synthesis, allowing for whitening effects even at low concentrations. It can be applied to cosmetics, pharmaceuticals, and food products for improving hyperpigmentation disorders such as melasma, solar lentigo, and age spots, enabling the development of both whitening product lines and health supplements from a single natural source.

‍

‍

Key Features:

• Whitening composition comprising deoxyvasicinone or its pharmaceutically acceptable salts, hydrates, or solvates as an active ingredient
• Whitening composition comprising an active ingredient that inhibits skin pigmentation or melanin production and has the structure of Formula 1
• Pharmaceutical composition for preventing or treating hyperpigmentation disorders, wherein the active ingredient is included in an amount of 1 ppm to 100 ppm based on the total composition
• Cosmetic and food compositions for preventing or improving hyperpigmentation disorders such as freckles, melasma, and age spots

‍

This invention was developed with support from the Ministry of Health and Welfare for the development of Korean-style ex vivo skin models and integrated animal-alternative efficacy evaluation technology based on 3D skin tissue.

‍